The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Celgene; Genentech/Roche; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; Lilly
 
Kyung-Hun Lee
Honoraria - AstraZeneca; Roche
Consulting or Advisory Role - Bayer; Eisai; Ono Pharmaceutical; Samsung Bioepis
 
Dae-Won Lee
No Relationships to Disclose
 
Tae Yong Kim
Consulting or Advisory Role - Eisai; Samsung Bioepis
Speakers' Bureau - Eisai; Roche; Samsung Bioepis; Sanofi/Aventis
 
Ju-Hee Bang
No Relationships to Disclose
 
Ah-Rong Nam
No Relationships to Disclose
 
Young Lee
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Qu Zhang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Marlon Rebelatto
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - AstraZeneca
 
Weimin Li
No Relationships to Disclose
 
Jin Won Kim
No Relationships to Disclose